Author

E. Ruoslahti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. M. Lowy· 1 shared C. Lu· 1 shared E. S. Mose· 1 shared H. Guo· 1 shared H.-B. Pang· 1 shared J. Guan· 1 shared J. Lahann· 1 shared J. V. Gregory· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. M. Lowy

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tumor-resident regulatory T cells in pancreatic cancer express the αvβ5 integrin as a targetable activation marker

K. Suzuki, Y. Kunisada, N. Miyamura, S. Eikawa, T. Hurtado de Mendoza, E. S. Mose, C. Lu, Y. Kuroda, E. Ruoslahti, A. M. Lowy, K. N. Sugahara

This study identifies αvβ5 integrin as a marker for activated tumor-resident Tregs in PDAC, showing that targeting it enhances immune checkpoint therapy.

bioRxiv · May 24, 2023 · PreprintCancer Biology

iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis

J. Guan, H. Guo, T. Tang, Y. Wang, Y. Wei, P. Seth, Y. Li, S. M. Dehm, E. Ruoslahti, H.-B. Pang

This paper demonstrates that iRGD-liposomes enhance the delivery and efficacy of AR-ASO in treating prostate cancer and bone metastasis without increasing toxicity.

bioRxiv · Jan 8, 2021Cancer Biology

Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy

J. V. Gregory, P. Kadiyala, R. Doherty, M. Cadena, S. Habeel, E. Ruoslahti, P. R. Lowenstein, M. G. Castro, J. Lahann

This study develops synthetic protein nanoparticles for GBM therapy, showing they deliver STAT3i siRNA to tumors, enhance radiation response, and induce immune memory in mice.

bioRxiv · Jan 9, 2020Bioengineering